



75 Victor Heights Parkway STE C
Victor, NY 14564
Ph: 585.337.4300
Fax: 585.396.7264
www.medicineshoppepharm.com
www.compoundingrochester.com

Updated Dosing & Concentrations (*replacing the 1mg/ml strength*)
compounded Semaglutide 2mg/ml or 3mg/ml in Sub Magna™ HMW
Adding Compounded Injectable Semaglutide Dosing Suggestions

Updated as of 6/27/24

Compounded Sublingual Semaglutide

As we have been producing compounded Semaglutide in Sub Magna™ HMW base for 2 months now, we participated in a national conference with other compounding facilities discussing updated dosing recommendations due to bioavailability findings.

Bioavailability of this compound is found to be 10% - 12% maximum with this sublingual delivery method, (still far superior to oral Rybelsus®, package insert reflects less than 1%). Using this information, as well as feedback from our initial patient group, we believe that the beginning and target doses should be increased to see the desired results. Additionally, to this date we have had no patients reporting adverse effects. This is reassuring that the dose can be safely increased. Please see the recommendations below.

Our recommendations have been updated to the following:

For patients that are GLP-1 naive, they should begin by taking **2mg/ml** as follows:

- 0.25 ml for 7 days, 0.5ml for 7 days, 1ml daily as their ongoing dosage, pending physician review for any further dose increase.

For patients that Currently or recently on GLP-1 injections, depending on how long since usage, by taking the **3mg/ml** as follows:

- 0.25ml for 7 days, then increase incrementally every 3-7 days as tolerated until their goal dose of 1ml / day.

Please rest assured that we are committed to finding the proper dosage to provide a meaningful outcome for your patients and believe that taking it slowly is the right way to establish this. We will continue to evaluate and update dosing as more information becomes available.

Compounded Injectable Semaglutide

Due to the intense demand for injectable semaglutide coupled with the FDA declared drug shortage, you may choose to write for a Compounded Injectable Semaglutide rather than the Sublingual option above.

We carry this is a 2.5mg/1ml concentration sourced from a FDA registered outsourcing facility. This would yield the suggested dosing to achieve the industry used drug concentrations. You are free to modify this as needed, but may need the syringe doses calculated if you want to deviate from the normal dosing.

Rybelsus® is a registered trademark of novo Nordisk A/S. No compounded Medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. Above is general proposed guidance that should be adapted to each individual prescriber's practice.



75 Victor Heights Parkway STE C
Victor, NY 14564
Ph: 585.337.4300
Fax: 585.396.7264
www.medicineshoppepharm.com
www.compoundingrochester.com

Suggested Dosing w/ Injection Calculations

Recommended Dosing	Dose (mg)	Volume Syringe (ml)	Total Volume (ml)
Mo #1 Weeks 1 - 4 0.25 mg / week *	0.25	0.1	1
Mo #2 Weeks 5 - 8 0.5 mg / week *	0.50	0.2	1
Mo #3 Weeks 9-12 1mg / week	1.00	0.4	2
Ongoing 1.7mg / week *	1.70	0.68	4
Ongoing 2.4mg / week	2.40	0.96	4

* May be more than (4) weeks in these doses

- Weeks 1-7 can be filled out of the first 1ml dispensed.
- Week #8 - #12 may be filled out of the 2ml dispensed for the ongoing doses.
- If writing for 1.7mg/week, we will dispense out of a 4ml quantity, so that will last 5 weeks.

Call any of our pharmacists Mon-Fri from 9am – 5pm if you need assistance. (585) 337-4300 Option #3, then #2.

Rybelsus® is a registered trademark of novo Nordisk A/S. No compounded Medication is reviewed by FDA for safety or efficacy. SubMagna™ HMW is a trademark of Kingdom Licensing. Above is general proposed guidance that should be adapted to each individual prescriber's practice.